ArticleOncoimmunology2015
Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 44 citations in OpenAlex.
- TLR4-dependent upregulation of IL-22-producing T cells in the bone niche links to the imbalance of bone homeostasis.Cellular & molecular biology letters · 2026Article
- T Cells Dysfunction in Multiple Myeloma.ImmunoTargets and therapy · 2025Review
- Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring.Immunologic research · 2024Article
- The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024Review
- Different evasion strategies in multiple myeloma.Frontiers in immunology · 2024Review
- One-Step Automatic Radiosynthesis and Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Indole-Based and Cyclopentenylindole-Based Analogues Containing Fluorine Group as PotentialPharmaceuticals (Basel, Switzerland) · 2023Review
- TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2023Article
- Eukaryotic Extension Factor 2 Kinase may Affect the Occurrence and Development of Glioblastoma Through Immune Cell Infiltration.Neurochemical research · 2022Article
- Migratory Engineering of T Cells for Cancer Therapy.Vaccines · 2022Review
- Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3.Cytotechnology · 2022Article
- Integrin subunit alpha V is a potent prognostic biomarker associated with immune infiltration in lower-grade glioma.Frontiers in neurology · 2022Article
- Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.Integrative biology : quantitative biosciences from nano to macro · 2021Article
- Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.Journal of clinical medicine · 2021Article
- Review
- Aryl Hydrocarbon Receptor Signaling Synergizes with TLR/NF-κB-Signaling for Induction of IL-22 Through Canonical and Non-Canonical AhR Pathways.Frontiers in toxicology · 2021Article
- Circulating Th22 cells, as well as Th17 cells, are elevated in patients with renal cell carcinoma.International journal of medical sciences · 2021Observational
- High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma.Scientific reports · 2020Article
- Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Giulia Di LulloTumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Magda MarcattiHematology and Bone Marrow Transplantation Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Silvia HeltaiTumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Emanuela BrunettoTumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Cristina TresoldiHematology and Bone Marrow Transplantation Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Attilio BondanzaDivision of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Leukenia Immunotherapy Group; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Chiara BoniniDivision of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Experimental Hematology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Maurilio PonzoniPathology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Molecular Oncology; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Giovanni TononDivision of Molecular Oncology; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Functional Genomics of Cancer Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Fabio CiceriHematology and Bone Marrow Transplantation Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Claudio BordignonMolMed SpA ; Milan, Italy ; Vita-Salute San Raffaele University ; Milan, Italy.
Maria Pia ProttiTumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico San RaffaeleIstituti di Ricovero e Cura a Carattere Scientifico · ITMolecular Oncology (United States) · USVita-Salute San Raffaele University · ITBipar · FR
Funding
Worldwide Cancer Research 12-0087
Abstract
There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22
Indexed as
Ab, antibody; BM, bone marrow; BMMCs, bone marrow mononuclear cells; DCs, dendritic cells; Dx, dexamethasone; ICS, intracellular cytokine staining; IFN, interferon; IL, interleukin; ISS, International Staging System; LCL, Epstein–Barr virus-transformed B lymphoblastoid cell line; Ln, lenalidomide; MGUS, monoclonal gammopathy of undetermined clinical significance; MM, multiple myeloma; MSC, mesenchymal stromal cell; PB, peripheral blood; PBMCs, peripheral blood mononuclear cells; pDCs, plasmacytoid dendritic cells; SMM, smoldering multiple myeloma; Th, T helper; TNF, tumor necrosis factor; Treg, regulatory T cells; WB, Western blotbone marrow mesenchymal stromal cellsbone marrow microenvironmentCD4+ T helper lymphocytesIL-22RA1interleukin-13interleukin-22multiple myelomaTh22 cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.